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Summary: Immunoassay of creatine kinase-MB provides numerical information, which makes it possible to estimate
quantitatively the diagnostic performance following myocardial infarction. Two graphical methods for such an
evaluation are presented. The relationship between technical sensitivity and specificity was analyzed using a
continuous function, the receiver-operator characteristic curve. Using this function, a diagnostic threshold ("upper
normal limit") was chosen, which balances both technical specificity and sensitivity on the first day following
infarction. On the second and third days this threshold caused a progressive loss of technical sensitivity. The
relationship between effectiveness and the prevalence of myocardial infarction in the tested population was
evaluated with a nomogram correlating these two quantities. With the chosen diagnostic threshold, effectiveness is
independent of prevalence on the first day, but the loss in technical sensitivity on subsequent days causes effectiv-
eness to decay when the prevalence is high.
Bewertungsmaße der diagnostischen Leistungsfähigkeit, angewendet auf die immunologische Kreatinkinase-MB-Be-
stimmung bei Herzinfarkt
Zusammenfassung: Die immunologische Bestimmung von Kreatinkinase-MB verschafft zahlenmäßige Ergebnisse,
welche die Anwendung quantitativer Bewertungsmaße der diagnostischen Leistungsfähigkeit nach Herzinfarkt ge-
stattet. Zwei Mittel für eine solche Wertbestimmung werden dargestellt. Die Wechselbeziehungen zwischen technischer
Empfindlichkeit und Spezifität wurden mittels einer kontinuierlichen Funktion, der „Receiver-Operator Characteristic
Curve" analysiert. Ein diagnostischer Schwellenwert ("obere Normalgrenze") wurde gewählt, bei welchem sowohl
die technische Empfindlichkeit wie die technische Spezifität am ersten Tag nach Infarkt im Gleichgewicht sind. Am
zweiten und dritten Tag verursacht dieser Schwellenwert einen zunehmenden Verlust an technischer Empfindlichkeit.
Die Beziehung der Effektivität (effectiveness) der Untersuchung zur Häufigkeit Von Herzinfarkt in der unter-
suchten Population wurde mit Hilfe eines Nomogramms bewertet, welches diese zwei Kenngrößen miteinander
korreliert. Mit dem gewählten Schwellenwert ist die Effektivität der Untersuchung am ersten Tag unabhängig von
der Krankheitshäufigkeit, aber der Verlust an technischer Empfindlichkeit verursacht bei hoher Krankheitshäufig-
keit in den folgenden Tagen eine Verminderung der Effektivität.
Introduction Recently, a creatine kinase-MB assay has been developed
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Experimental Procedure
Subjects
Patients with myocardial infarction (N=42) and patients with
suspected but unconfirmed myocardial infarction (N=98) were
investigated. These diagnostic classifications were established by
a review of clinical history, laboratory data and electrocardio-
graphic data following the patient's discharge.
Samples were obtained on three days following infarction or
following admission for suspected infarction (days 1, 2 and 3).
Venous blood was collected in vacuum tubes (CORVACR;
Corning Medical, 11 North Street, Medfield, MA 02052),
analyzed immediately or stored for no more than 18 hours at
4°C until assayed.
Immunological assay of creatine kinase-MB
A spectrophotometer equipped with a cuvette holder thermq-
statted at 37°C was used (Model 25; Beckman Instruments Inc.,
Fullerton, CA 92634). The assay mixture consisted of 10 μΐ
reagent containing: 100 mmol/1 triethanolamine buffer pH 7.0;
35 mmol/1 creatine phosphate; 20 mmol/1 glucose; 9 mmol/1
glutathione; 10 mmol/1 AMP; > 1.2 kU/1 glucose 6-phosphate
dehydrogenase; 11.2 kU/1 hexokinase, and 800 U/l creatine
kinase-MM inhibiting antibodies from the goat (E. Merck, Darm-
stadt, West-Germany). Diadenosine pentaphosphate was added
to this assay mixture in a final concentration of 10 μπιοΐ/ΐ.
Following addition of the sample, the mixture was preincubated
for 7 minutes and the absorbance at 340 nm was then recorded
for 3 minutes to calculate enzyme activity using a value of
6,3001 · mol"1 · cm'1 as the molar absorbance coefficient of
NADPH. Results were expressed in U/l.
Electrophoretic assay of creatine kinase-MB
Creatine kinase isoenzymes were separated on 10g/l agarose
gel and visualized by overlay with the creatine kinase assay
mixture of Oliver (7). Relative activities of isoenzyme fractions
were estimated by densitometric scanning at 340 nm. Absolute
activity of creatine kinase-MB was calculated by multiplying
the relative activity of this fraction (percent) with the total
creatine kinase activity.
Assays of total creatine kinase, aspartate aminotrans-
ferase (EC 2.6.1.1), lactate dehydrogenase (EC 1.1.1.27),
and 2-hydroxybutyrate dehydrogenase
All four enzymes were assayed at 37°C on a mechanized, kinetic
enzyme analyzer (System TR; Beckman Instrument Inc.). The
creatine kinase assay of Oliver (7), the aspartate aminotransferase
assay ofAmador & Wacker (8), the lactate dehydrogenase assay
of Gay.McComb &. Bowers (9) and the aspartate aminotrans-
ferase assay of Rosalki et al (10) were used.
Statistical analysis
The terms technical sensitivity, technical specificity and effec-
tiveness were used as previously defined (11). Technical sen-
sitivity is the probability of a positive test among patients with
an infarct, and technical specificity is the probability of a
negative test among patients without an infarct:
Technical Sensitivity ·
True Positives DT
True Positives + False Negatives DT + DT
Technical Specificity =
True Negatives DT
True Negatives + False Positives DT + DT
Effectiveness (E) is the sum of the population proportions of
true positives and true negatives:
E = P(DT)
Results
To establish the relationships of the immunological
creatine kinase-MB assay to other laboratory indicators
of myocardial infarction, the activities measured by this
assay were correlated with the creatine kinase-MB
activities derived from electrophoretic separation, as
well as with the total creatine kinase, aspartate arnino-
transferase, 2-hydroxybutyrate dehydrogenase and
lactate dehydrogenase activities (tab. 1). Correlations
with creatine kinase-MB by electrpphpresis, total creatine
kinase and aspartate aminotransferase (three parameters
known to be early indicators of myocardial infarction),
were essentially equivalent, ranging from 0.62 to 0.68.
Conversely, correlations both with 24iydroxybutyrate
dehydrogenase and with lactate dehydrogenase, which
are known to rise later following infarction, were lower.
Tab. 1. Correlation coefficients, r, for creatine kinase-MB
immunological assays and other enzyme assays in patients
with myocardial infarction. N = 114.
Enzyme
95% Confidence
r interval for r Significance
Creatine kinase-MB,
Electrophoresis 0.68
Creatine kinase 0.62
Aspartate amino- 0.64
transferase
2-Hydroxybutyrate 0.41
dehydrogenase
Lactate dehydrogenase 0.20
0.56-0.77
0.48-0.74
0.51-0.74
0.23^0.56
0.01-0.38
P < 0.001
P < 0.001
P < 0.001
P < 0.001
P < 0.01
09
Specificity
Fig. 1. Receiver-Operator Characteristic (ROC) curves for immu^
nological creatine kinase-MB assays on the three days
folio wing infarction. The ideal test which is. characterized
by a 1.0 sensitivity and a 1.0 specificity would plot on the
upper right-hand corner, trie operating points correspon-
ding to a decision threshold of 15 U/l are circled. (Note
different scales used for specificity and sensitivity).
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The interdependence of technical sensitivity and speci-
ficity of immunological creatine kinase-MB assays was
analyzed by the ROC function (fig. 1). Findings from
the first, second and third days (24 hour periods)
following infarction were separated. Using different
creatine kinase-MB values as decision thresholds to
distinguish normal from elevated findings, results from
infarcted patients were classified into true positives and
false negatives to calculate technical sensitivity for
each day. All results from uninfarcted patients were
classified into true negatives and false positives to cal-
culate technical specificity. Thus, as the decision
threshold was raised stepwise from zero to 60 U/l in
analyzing data from day one, technical sensitivity
decreased while technical specificity increased, since a
decreasing number of patients were classified as
positives.
When an activity of 15 U/l was used to separate
negatives from positives, the two technical properties
were equivalently balanced with a sensitivity of 93%
and a specificity of 95%. We have subsequently used this
value as our criterion to distinguish normal from
elevated creatine kinase-MB values. On the second and
third days, the overall discriminatory power diminished
increasingly as the ROC curves evidenced a less favorable
relationship between sensitivity and specificity. Using
again 15 U/l as the discriminatory threshold, sensitivity
on the second day was 72%, and on the third day 28%.
Figure 2 illustrates the dependence of the effectiveness of
immunological creatine kinase-MB assays upon the
100
Fig. 2. Effectiveness of immunological creatine kinase-MB
assays on different days foUpwiiig infarction as a function
of the prevalence of patients with myocardial infarction
in the tested population. If all patients are infarcted (P
(D) = 100%), effectiveness is equal to technical sensitivity;
if no patients are infarcted (O(D) = 0%), effectiveness is
equal to technical specificity. Effectiveness for other pre-
valences is obtained by linear interpolation -between
these limiting values.
prevalence of patients with myocardial infarction in the
tested population. With a discriminatory threshold of 15
U/l effectiveness was practically insensitive to disease
prevalence on the first day. Using the same decision
threshold on subsequent days produced a dramatic decay
of effectiveness at high disease prevalence, whereas
effectiveness at low prevalences was not similarly affected.
Discussion
Traditionally, the evaluation of new laboratory assays
focuses on technical and biochemical properties. Much
less attention is paid to the diagnostic performance of the
assays, even though this is the most crucial determinant of
practical utility. Opinions about the immunological creatine-
kinase-MB assay illustrate these views. From a purely bio-
chemical viewpoint, the inability of this procedure to
distinguish activity due to creatine kinase-BB from that
due to creatine kinase-MB has caused concern. From a
diagnostic viewpoint, a lack of chemical specificity in
principle need not invalidate a procedure (12). This is
particularly true if interferences, such as creatine kinase-
BB in blood, are rarely encountered (6).
Concern with technical aspects of creatine kinase-MB
assay has led to modifications of reaction temperature
(4, 5, 13, 14), sulfhydryl activators (17,18), inhibitors
of adenylate kinase (EC 2.7.4.3) (I.e. (16)) and blanking
procedures. These variables are of secondary relevance for
the present purpose. The important technical feature of
immunological creatine kinase-MB assay is the quanti-
tative nature of results which facilitates the statistical
evaluation of diagnostic performance.
A useful assessment of diagnostic performance rests on
two foundations: Scrupulous retrospective case review
and analytical summation which facilitates cogent con-
clusions. Many previous evaluations of laboratory
indicators of myocardial infarction fall short of dealing
adequately with the following issues: The definition of
the normal range used to classify the results, attention to
the elapsed time since the pathogenic event, and in-
clusion of the prevalence of infarction in the tested
population. Experimental observations can only become
relevant to clinical practice if these points are properly
considered.
First, a reference range derived previously from obser-
vations in subjects without myocardial infarction is
generally used to separate physiological from pathological
findings (14, 19, 20). However, from a diagnostic view-
point such a threshold usually is not the most appropriate.
Joint consideration of findings typical for diseased
subjects as well as nondiseased subjects is preferable
(21). The ROC function provides a convenient way to con-
sider these groups simultaneously (22). Technical
sensitivity can be related to technical specificity in a
continuous function. Thus, different decision thresholds
can be selected to tailor optimal outcome in different
J. Clin. Chem. Clin. fiiochem. / Vol. 17,1979 / No. 6
362 Werner and Mohrbacher: Immunological creatine-kinase MB assay in myocardial infarction
circumstances. Further, the ROC function permits com-
parison of the same test applied in different conditions
such as different stages in the evolution of myocardial
infarction (fig. 1). Similarly, the overall discriminatory
power of different tests can be contrasted with each
other to select the best one.
Second, the diagnostic performance of enzyme assays is
typically evaluated on the basis of serial measurements
following myocardial infarction. If the calculated dia-
gnostic properties, such as sensitivity and specificity do
not relate the statistical odds to sampling at a specific
time, biased conclusions result.
Frequently, the rules for the serial sampling or for the
choice of selected values on which the calculation of
technical sensitivity is based are not detailed (14, 19).
In other instances only peak enzyme activities in the
series are utilized for analysis even though these occur
at different times following infarction and can only be
identified retrospectively (20). However, the test's
varying capabilities at different points in time is relevant,
as patients present themselves for diagnosis at different
intervals following infarction. For this reason, we have
analyzed all observations from all patients after classifying
them according to time since the infarct. The diagnostic
power of creatine kinase and creatine kinase-MB is
greatest within the first 24 hours after the onset of
retrosternal pain (19, 23). The later deterioration is
due to a loss of technical sensitivity, while technical
specificity remains unaffected (fig. 1).
Third, any evaluation of diagnostic utility should include
the prevalence of the diagnosed condition in the tested
population. Two parameters of test performance which
take prevalence into account have been proposed. These
quantities have been called alternatively "positive and
negative predictive value" (24) and "diagnostic sensitivity
and specificity" (11). The experience contained in these
values can be condensed into a single number which has
been termed the effectiveness of a test (11). This
quantity considers the odds of a true positive -and of a
true negative jointly. Construction of a simple nomo-
gram to survey effectiveness as a continuous function
at different prevalences of disease requires only the
values of technical sensitivity and specificity. Figure 2
shows that the diagnostic threshold chosen for creatine
kinase-MB renders effectiveness independent of disease
prevalence on the day of infarction when the assay has
its greatest utility. On subsequent days that same thre-
shold provides less technical sensitivity than a lower one
might have, and consequently would compromise
effectiveness most were there a high prevalence of
infarcted patients in the tested population.
The inferences from these propositions are:
1. The relationship between technical sensitivity and
specificity which should determine normal limits is
conveniently visualized in the ROC curve.
2. The elapsed time since infarction should be ex-
plicitly considered when test performance is
evaluated.
3. A nomogram of effectiveness provides a simple
means to include and evaluate the influence of
prevalences on test performance.
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